EP1719762B1 — Novel pyridine derivative and pyrimidine derivative (1)
Assigned to Eisai R&D Management Co Ltd · Expires 2012-06-27 · 14y expired
What this patent protects
A compound represented by the following general formula, a salt thereof, or a hydrate of either. They have excellent inhibitory activity against a hepatocyte growth factor receptor (HGFR) and have antitumor activity, angiogenesis inhibitory activity, or cancer metastasis inhibito…
USPTO Abstract
A compound represented by the following general formula, a salt thereof, or a hydrate of either. They have excellent inhibitory activity against a hepatocyte growth factor receptor (HGFR) and have antitumor activity, angiogenesis inhibitory activity, or cancer metastasis inhibitory activity. (In the formula, R1 means C1-6 alkyl, etc.; R2 and R3 each means hydrogen; R4, R5, R6, and R7 are the same or different and each means hydrogen, halogeno, C1-6 alkyl, etc.; R8 means hydrogen, etc.; R9 means C1-6 alkyl, etc.; V1 means oxygen, etc.; V2 means oxygen or sulfur; W means -NH-, etc.; X means -CH=, nitrogen, etc.; and Y means oxygen, etc.)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.